Salivary Levels of S100A8, S100A9 and S100A8/9 in Periodontal Health and Disease: A Cross-sectional Study

被引:0
|
作者
George, Annie Kitty [1 ,2 ]
Malaiappan, Sankari [2 ]
Narayan, Vivek [3 ]
Jayaraman, Selvaraj [4 ]
Suresh, Nidhita [2 ]
机构
[1] Pushpagiri Coll Dent Sci, Dept Periodont, Thiruvalla 689107, Kerala, India
[2] Saveetha Inst Med & Tech Sci, Saveetha Dent Coll & Hosp, Dept Periodont, Chennai, India
[3] Govt Dent Coll, Dept Publ Hlth Dent, Kottayam, Kerala, India
[4] Saveetha Dent Coll & Hosp, Saveetha Inst Med & Tech Sci, Dept Biochem, Chennai, India
关键词
Alarmins; Gingivitis; Periodontitis; Proteomics; Saliva; CALPROTECTIN; SERUM; CLASSIFICATION; MARKERS;
D O I
10.7860/JCDR/2024/69936.19754
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Damage Associated Molecular Patterns (DAMPs) can initiate and amplify immune responses and can play an important role in the sustenance and progression of periodontal diseases. S100A8, S100A9 and their heterodimer, S100A8/9, are DAMPs or alarmins currently being evaluated for their potential as biomarkers in periodontal diseases. Aim: To quantify and compare salivary levels of S100A8, S100A9 and S100A8/9 in periodontal health, gingivitis or stage 1 periodontitis and stages 3 or 4 periodontitis. Materials and Methods: A cross-sectional analytical study was carried out in the Department of Periodontics, Saveetha Dental College and Hospital, Chennai, India, from December 2022 to February 2023. Periodontal examination and saliva sample collection were done for sixty-eight consecutively enrolled subjects who met the inclusion and exclusion criteria. Study subjects were categorised as group 1, which comprised participants with clinical periodontal health (n=20), group 2, subjects with gingivitis or stage 1 periodontitis (n=20), and group 3, which included patients with stages 3 or 4 periodontitis (n=28). Detailed clinical examination and periodontal charting were done in all study subjects. Saliva samples were processed and stored at -80 degrees C, and enzyme-linked immunosorbent assay was done to quantify S100A8, S100A9 and S100A8/9. Data were analysed using International Business Machines (IBM) Statistical Package for the Social Sciences (SPSS) software version 25.0. Salivary levels of S100A8, S100A9 and S100A8/9 were expressed as mean and standard deviation values. Mean values of the three salivary proteins were compared using the non parametric Kruskal-Wallis test. Bonferroni adjusted pairwise comparisons were also done. The p-values less than 0.05 were considered statistically significant. Results: The mean age of study participants was 38.97 +/- 7.62 years. Salivary levels of S100A8 were 41.34 +/- 14.34, 141.95 +/- 185.25 and 901.37 +/- 65.60 pg/mL in groups 1, 2 and 3, respectively. A statistically significant difference was present among the three groups for mean salivary levels of S100A8 (p-value<0.001). Pairwise comparisons showed that salivary S100A8 values in group 3 were significantly higher than the values observed in clinical health (group 1) (p-value<0.001) and those seen in the gingivitis or stage 1 periodontitis group (group 2) (p-value<0.001). Mean salivary levels of S100A9 and S100A8/9 did not show any statistically significant differences between the groups. Conclusion: There is an altered expression of S100A8, S100A9 and S100A8/9 in periodontal diseases compared to clinical health. Salivary levels of S100A8 are markedly different in cases of advanced periodontal destruction than in periodontal health and early stages of periodontal disease. Salivary S100A8 merits potential as a biomarker for periodontal diseases.
引用
收藏
页码:ZC36 / ZC40
页数:5
相关论文
共 50 条
  • [1] S100A8 and S100A9 in Cancer
    Chen, Yu
    Ouyang, Yuzhen
    Li, Zhixin
    Wang, Xiufang
    Ma, Jian
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2023, 1878 (03):
  • [2] S100A8 and S100A9 in Cardiovascular Biology and Disease
    Averill, Michelle M.
    Kerkhoff, Claus
    Bornfeldt, Karin E.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2012, 32 (02) : 223 - 229
  • [3] Chemotactic activity of S100A8 and S100A9
    Roth, J
    Vogl, T
    Sunderkötter, C
    Sorg, C
    JOURNAL OF IMMUNOLOGY, 2003, 171 (11): : 5651 - 5651
  • [4] S100A8 and S100A9 in experimental osteoarthritis
    Zreiqat, Hala
    Belluoccio, Daniele
    Smith, Margaret M.
    Wilson, Richard
    Rowley, Lynn A.
    Jones, Katie
    Ramaswamy, Yogambha
    Vogl, Thomas
    Roth, Johannes
    Bateman, John F.
    Little, Christopher B.
    ARTHRITIS RESEARCH & THERAPY, 2010, 12 (01)
  • [5] S100A8 and S100A9 in inflammation and cancer
    Gebhardt, Christoffer
    Nemeth, Julia
    Angel, Peter
    Hess, Jochen
    BIOCHEMICAL PHARMACOLOGY, 2006, 72 (11) : 1622 - 1631
  • [6] S100A8 and S100A9 in inflammatory diseases
    Roth, J
    Goebeler, M
    Sorg, C
    LANCET, 2001, 357 (9261): : 1041 - 1041
  • [7] S100A8 and S100A9 in experimental osteoarthritis
    Hala Zreiqat
    Daniele Belluoccio
    Margaret M Smith
    Richard Wilson
    Lynn A Rowley
    Katie Jones
    Yogambha Ramaswamy
    Thomas Vogl
    Johannes Roth
    John F Bateman
    Christopher B Little
    Arthritis Research & Therapy, 12
  • [8] Neurodegenerative effects of S100A8 and S100A9 in Parkinson's disease
    Lee, J. S.
    Kashif, A.
    Kim, G.
    Hong, M. H.
    Kim, I. S.
    FEBS OPEN BIO, 2022, 12 : 199 - 199
  • [9] Involvement of S100A8 and S100A9 in nonischaemic cardiomyopathy
    Lin, Qiu-Yue
    Jiang, Wen-Xi
    Li, Hui-Hua
    CLINICAL AND TRANSLATIONAL DISCOVERY, 2025, 5 (02):
  • [10] S100A8 and S100A9 regulate lung metastasis
    Maru, Yoshiro
    SEIKAGAKU, 2007, 79 (09): : 871 - 874